Ubs Group Ag Rezolute, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Rezolute, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 3,037,168 shares of RZLT stock, worth $18.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,037,168

Previous 616,515 392.63%

Holding current value

$18.8 Million

Previous $1.79 Million 657.97%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.47 - $4.46 $5.98 Million - $10.8 Million	2,420,653 Added 392.63%	3,037,168 $13.5 Million
Q1 2025 May 13, 2025	BUY	$2.73 - $5.57 $777,274 - $1.59 Million	284,716 Added 85.81%	616,515 $1.79 Million
Q4 2024 Feb 14, 2025	BUY	$4.08 - $5.96 $1.35 Million - $1.97 Million	329,756 Added 16140.77%	331,799 $1.58 Million
Q3 2024 Nov 14, 2024	SELL	$4.13 - $5.31 $6,488 - $8,342	-1,571 Reduced 43.47%	2,043 $9,000
Q2 2024 Aug 13, 2024	BUY	$2.29 - $5.79 $8,276 - $20,925	3,614 New	3,614 $15,000
Q4 2023 Feb 09, 2024	BUY	$0.74 - $1.24 $161,247 - $270,198	217,902 New	217,902 $215,000
Q1 2023 May 12, 2023	BUY	$1.79 - $2.87 $3,680 - $5,900	2,056 New	2,056 $3,000
Q2 2022 Aug 10, 2022	SELL	$2.6 - $3.85 $7,150 - $10,587	-2,750 Reduced 61.23%	1,741 $5,000
Q1 2022 May 16, 2022	BUY	$2.27 - $5.1 $415 - $933	183 Added 4.25%	4,491 $15,000
Q4 2021 Feb 14, 2022	BUY	$4.21 - $7.61 $2,681 - $4,847	637 Added 17.35%	4,308 $21,000
Q3 2021 Nov 15, 2021	BUY	$7.45 - $13.66 $20,509 - $37,605	2,753 Added 299.89%	3,671 $27,000
Q2 2021 Aug 13, 2021	BUY	$6.11 - $15.99 $2,040 - $5,340	334 Added 57.19%	918 $13,000
Q1 2021 May 12, 2021	SELL	$6.83 - $17.3 $2,472 - $6,262	-362 Reduced 38.27%	584 $4,000
Q4 2020 Feb 11, 2021	BUY	$11.99 - $24.05 $11,342 - $22,751	946 New	946 $11,000

Others Institutions Holding RZLT

# of Institutions

Shares Held

59.5M

Call Options Held

687K

Put Options Held

19K

View Full List

About Rezolute, Inc.

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $241M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

More about RZLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account